Sodium phosphate (mono-, di-, and tribasic)

What this is

Scientifically, sodium phosphates are part of a broader family of inorganic phosphate additives. Phosphorus is an essential nutrient and naturally present in foods, so risk assessment considers total dietary phosphorus, not only the additive. FDA treats sodium phosphate (mono-, di-, and tribasic) as GRAS when used under good manufacturing practice, and international systems identify the INS/E 339 forms for food-additive use. EFSA’s 2019 re-evaluation set a group acceptable daily intake of 40 mg/kg body weight per day as phosphorus; it found no concern for genotoxicity, carcinogenicity, or developmental toxicity, but estimated total phosphate exposure could exceed the ADI for children and high-consuming adolescents, and the ADI does not apply to people with moderate or severe kidney impairment. JECFA’s older group MTDI is 70 mg/kg body weight as phosphorus. Regulators broadly allow sodium phosphates, but with category-specific use limits and post-EFSA EU technical-data follow-up.

Safety Review

The critical endpoints experts review in safety assessments. This is not a prediction of harm.

EFSA found no genotoxicity, carcinogenicity, or developmental-toxicity concern, so this is not a classic chemical-toxicity issue. The biological concern is phosphate burden: children and high-consuming adolescents may exceed the group ADI, and kidney-vulnerable people are excluded from the ADI because impaired phosphate handling changes risk.